Safety, efficacy seen for Sjögren’s therapy ianalumab in pair of trials
Novartis' therapy candidate ianalumab safely and effectively eased disease activity for adults with active Sjögren's in two clinical trials.| Sjogren's Disease News
Novartis' therapy candidate ianalumab safely and effectively eased disease activity for adults with active Sjögren's in two clinical trials.| Sjogren's Disease News
Prompt treatment for Sjögren’s was found to improve recovery, and reduce the risk of recurrence, in patients who develop ischemic stroke.| Sjogren's Disease News
Newborns of mothers with primary Sjögren’s disease may be at a higher risk of developing heart conditions, a study in China says.| Sjogren's Syndrome News
The dysfunction of regulatory T-cells, or Tregs, drives the development of Sjögren's disease, according to a new mouse study.| Sjogren's Syndrome News
Andrea Lobo is a science writer for Sjogren's Syndrome News with a PhD in cell biology/neurosciences. She covers the latest news and information on a variety of Sjogren's topics.| Sjogren's Syndrome News
The proteins CTSS and GSTO1 were able to accurately distinguish people with Sjögren's syndrome from people without the condition.| Sjogren's Syndrome News
Category archive page for News.| Sjogren's Syndrome News
